Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CMR

Financiado

Cerrado

Chromatin modifiers in reprogramming

Transcription factor-based reprogramming has enabled the generation of induced pluripotent stem cells (iPSCs). IPSCs can be used in disease modelling and derivation of rejection-free mature cell types for cell-replacement therapie... ver más

28/02/2017

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

KOC UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

0.00€ | Lider

Proyectos interesantes

BFU2016-80899-P

Medical Technol...

Data Science

194K€ Cerrado

SAF2016-74962-R

Medical Technol...

Data Science

182K€ Cerrado

dynamicmodifications

Medical Technol...

Data Science

2M€ Cerrado

CellKarma

Medical Technol...

Data Science

1M€ Cerrado

PGC2018-098626-B-I00

Medical Technol...

Data Science

106K€ Cerrado

ReachingCompleteness

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

KOC UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Transcription factor-based reprogramming has enabled the generation of induced pluripotent stem cells (iPSCs). IPSCs can be used in disease modelling and derivation of rejection-free mature cell types for cell-replacement therapies. Proof-of-principle studies show that a number of genetic, complex, and malignant diseases can benefit from such cell-based therapies. Despite their immense potential, technical obstacles remain in the generation of iPSCs. This project is aimed at generating tools to overcome these obstacles by elucidating the molecular mechanisms of reprogramming. The fundamental mechanisms by which somatic cell identity gets replaced by pluripotent cell identity during reprogramming are poorly defined. Cellular identity is largely controlled by chromatin-based epigenetic mechanisms and while there is increasing knowledge about the distinct epigenetic states before and after reprogramming, the role of key chromatin modifier genes in reprogramming remains largely unexplored. Previous research has indicated that it is possible to identify key chromatin-based modulators of reprogramming and use this knowledge to increase reprogramming efficiency and replace exogenous factors with chemical compounds (Onder et al. 2012). To extend these studies further, identify novel chromatin-based regulators of reprogramming, and understand the molecular mechanisms of these regulators, this project will: (1) elucidate the mechanism by which inhibition of histone methyl-transferases Suv39H1 and Setd2 enhances reprogramming, and (2) identify histone demethylases that act as positive or negative regulators of reprogramming. This project will not only contribute to our understanding of the molecular basis of reprogramming, but also proposes to use that knowledge to facilitate efficient generation of iPSCs which will have significant clinical uses in the near future.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores